EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Greater Reductions in Hepatitis B Core-Related Antigen Associated with Switching from Entecavir to Tenofovir Alafenamide Compared with Continued Entecavir Therapy: A Retrospective Observational Study

Masanori Fukushima iD, Satoshi Miuma iD, Yasuhiko Nakao iD, Ryu Sasaki iD, Masafumi Haraguchi, Hisamitsu Miyaaki

Journal of Clinical Medicine · 22.05.2026 · 15 (11) · 4021

DOI: 10.3390/jcm15114021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 22.05.2026. Verfasst von Masanori Fukushima und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Hepatitis B core-related antigen (HBcrAg) is a surrogate marker that reflects the transcriptional activity of covalently closed circular DNA (cccDNA). However, the impact of switching nucleos(t)ide analogs on HBcrAg levels remains unclear. The current study evaluated changes in HBcrAg levels following a switch from entecavir (ETV) to tenofovir alafenamide (TAF) compared with continued ETV therapy.

Methods

This retrospective study included patients with chronic hepatitis B who either switched from ETV to TAF between 2017 and 2022 (ETV–TAF group) or continued ETV therapy during the same period (ETV group). HBcrAg levels were measured annually, and longitudinal changes over 3 years were analyzed based on an index year defined for each patient. Propensity score matching for age, sex, HBcrAg levels, liver transplantation status, and ETV treatment duration yielded 10 patients per group.

Results

Baseline characteristics were well balanced after matching. HBV DNA and HBsAg levels remained suppressed in both groups throughout follow-up. The ETV-TAF group showed greater declines in HBcrAg than the ETV group at year 2 (−0.20 vs. −0.10 log U/mL, p = 0.007) and year 3 (−0.30 vs. −0.10 log U/mL, p = 0.006). No virological breakthroughs occurred.

Conclusions

Switching from ETV to TAF was associated with greater reductions in HBcrAg levels over 3 years than continued ETV therapy, even in patients with suppressed HBV DNA. These findings suggest that switching to TAF may be associated with further suppression of viral transcriptional activity reflected by HBcrAg reduction and support its potential clinical utility for achieving deeper viral suppression.

Schlagwörter

Stichwörter der Autor:innen

entecavirhepatitis B core-related antigenswitchingtenofovir alafenamide

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan.

ORCID-Profile: Masanori Fukushima, Satoshi Miuma, Yasuhiko Nakao, Ryu Sasaki

Zitieren

APA

Fukushima, M., Miuma, S., Nakao, Y., Sasaki, R., Haraguchi, M., & Miyaaki, H. (2026). Greater Reductions in Hepatitis B Core-Related Antigen Associated with Switching from Entecavir to Tenofovir Alafenamide Compared with Continued Entecavir Therapy: A Retrospective Observational Study. Journal of Clinical Medicine, 15(11), 4021. https://doi.org/10.3390/jcm15114021

Vancouver

Fukushima M, Miuma S, Nakao Y, Sasaki R, Haraguchi M, Miyaaki H. Greater Reductions in Hepatitis B Core-Related Antigen Associated with Switching from Entecavir to Tenofovir Alafenamide Compared with Continued Entecavir Therapy: A Retrospective Observational Study. Journal of Clinical Medicine. 2026;15(11):4021. doi:10.3390/jcm15114021

BibTeX
@article{Fukushima2026,
  author = {Fukushima, Masanori and Miuma, Satoshi and Nakao, Yasuhiko and Sasaki, Ryu and Haraguchi, Masafumi and Miyaaki, Hisamitsu},
  title = {Greater Reductions in Hepatitis B Core-Related Antigen Associated with Switching from Entecavir to Tenofovir Alafenamide Compared with Continued Entecavir Therapy: A Retrospective Observational Study},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {4021},
  doi = {10.3390/jcm15114021}
}
Kostenlos starten →